GlassScriptPhysician profile
Jing R Lu
NPI 1538794045
$2,557.49
in general payments reported to CMS, 2019-2025
32 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $638 · 2023: $716 · 2024: $211 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.34 | 2021-2024 | |
| Exact Sciences Corporation | $323.44 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $224.10 | 2022-2025 | Trelegy Ellipta |
| Ibsa Pharma INC. | $177.04 | 2021-2023 | Tirosint, Licart |
| Amarin Pharma, INC. | $134.25 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $110.08 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $109.20 | 2021-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $107.48 | 2021-2025 | Vaxneuvance, Pneumovax 23, Capvaxive |
| Pfizer INC. | $103.09 | 2021-2024 | |
| Lilly USA, LLC | $100.60 | 2021-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $89.16 | 2021-2025 | Trintellix |
| Philips North America LLC | $83.11 | 2025 | Vest Therapy Und |
| Ironwood Pharmaceuticals, INC | $75.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.16 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $52.70 | 2022-2023 | Prehevbrio |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.82 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $42.22 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $38.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $33.73 | 2024-2025 | Rexulti |
| Hikma Pharmaceuticals USA | $32.26 | 2023 | Ryaltris, Mitigare |
| Smith+Nephew, INC. | $27.90 | 2025 | Collagenase Santyl |
| Nestle Healthcare Nutrition INC. | $27.27 | 2023 | |
| Agios Pharmaceuticals, INC. | $22.61 | 2025 | Pyrukynd |
| Biohaven Pharmaceutical Holding Company LTD. | $20.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.00 | 2022 | |
| Vivus LLC | $19.56 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.86 | 2023 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $17.27 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.26 | 2022 | |
| Nevro Corp. | $15.03 | 2021 | |
| Lundbeck LLC | $14.93 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jing Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.